Roche Holding AG (RHHBY)
| Market Cap | 350.11B +37.8% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.98 +30.6% |
| Shares Out | n/a |
| PE Ratio | 22.92 |
| Forward PE | 16.83 |
| Dividend | 0.97 (1.78%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 321,075 |
| Open | 55.69 |
| Previous Close | 55.08 |
| Day's Range | 55.18 - 55.81 |
| 52-Week Range | 37.51 - 60.85 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 57.23 (+3.12%) |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $57.23, which is an increase of 3.12% from the latest price.
News
Labcorp launches FDA-approved PTEN companion diagnostic for prostate cancer
Labcorp (LH) announced the nationwide availability of Roche’s (RHHBY) VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic test approved by the U.S. FDA to determine PT...
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
PARIS--(BUSINESS WIRE)--Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, ...
Genprex announces collaboration with Roche Diagnostics
Genprex (GNPX) announced its collaboration with Roche Diagnostics (RHHBY) to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Building on promising preclini...
Roche sues Biocon over proposed breast-cancer drug copy
Roche's Genentech has sued Indian biopharmaceutical company Biocon in New Jersey federal court, alleging its proposed biosimilar of Genentech's blockbuster breast-cancer drug Perjeta would infringe Ge...
Swiss Market Index Rises as US-Iran Pause Lifts Sentiment, Defensive Pharma Giants Anchor Gains Monday
The Swiss Market Index rose as U.S.-Iran tensions eased, boosting European markets and lowering oil prices. Defensive stocks like Roche and Novartis led the gains amid ongoing geopolitical uncertainti...
How Roche Unexpectedly Buoyed IBD Stock Of The Day TG Therapeutics
TG Therapeutics is Friday's IBD Stock Of The Day after shares rebounded into a profit-taking zone on key comments from chief rival Roche.
Roche Receives FDA Clearance For Cobas BV/CV Assay To Improve Vaginitis Diagnosis
(RTTNews) - Roche (RHHBY) announced that the U.S. FDA has granted 510(k) clearance for its cobas BV/CV assay, a molecular diagnostic test designed to simultaneously detect Bacterial vaginosis (BV) and...
Roche Holding's Vaginitis Diagnostic Test Secures FDA 510(k) Clearance
(RTTNews) - Friday, Roche Holding AG (RHHBY.PK) announced that the U.S. Food and Drug Administration has granted 510(k) clearance to its cobas Bacterial vaginosis/Candida vaginitis or BV/CV assay for ...
Roche announces EMA’s CHMP recommended approval of Susvimo
Roche (RHHBY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended the approval of Susvimo 100 mg/mL for the treatment of neovascu...
Roche receives FDA 510(k) clearance for cobas BV/CV assay
Roche (RHHBY) announced that it has received U.S. FDA 510(k) clearance for its cobas BV/CV assay. This molecular diagnostic test provides results for both Bacterial vaginosis and Candida vaginitis fro...
Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
The new PCR test uses clinician-collected or clinician-instructed, self-collected vaginal swab specimens to simultaneously detect organisms associated with Bacterial vaginosis (BV) and Candida vaginit...
Roche Announces Positive CHMP Recommendation For Susvimo
(RTTNews) - Roche (RO.SW, ROG.SW) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Susvimo 100 mg/mL for the treatment of n...
CHMP recommends EU approval of Roche's Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Basel, 24 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Susv...
Roche (RHHBY) Reports H1 Earnings, Shares Surge 5% Despite Mixed Results
Roche (RHHBY) Reports H1 Earnings, Shares Surge 5% Despite Mixed Results
Roche Cuts Generic Sales Hit to $736 Million, Shares Jump 3.2%
Roche Cuts Generic Sales Hit to $736 Million, Shares Jump 3.2%
Roche Holding AG Earnings Call Transcript: H1 2026
Core operating profit rose 10% year-over-year, outpacing 6% sales growth, with margin expansion and strong contributions from both Pharma and Diagnostics. Pipeline momentum remains high with five FDA priority reviews and major launches in diagnostics and obesity. Currency headwinds and China reforms continue to impact results.
Roche Holding AG Quarterly report: H1 2026
Roche Holding AG has published its H1 2026 quarterly earnings report on July 23, 2026.
Roche Holding AG Slides: H1 2026
Roche Holding AG has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 23, 2026.
Roche Holding AG Earnings release: H1 2026
Roche Holding AG released its H1 2026 earnings on July 23, 2026, summarizing the period's financial results.
Roche confirms FY26 outlook
Roche (RHHBY) expects an increase in Group sales in the mid single digit range for 2026. Core earnings per share are targeted to develop in the high single digit range.
Roche's GLP-1 drug showing stronger weight loss than rival, says CEO
Thomas Schinecker, CEO of Roche, discusses U.S. pharmaceutical tariffs, the company's product pipeline, global manufacturing, and the impact of AI on the business.
Roche Holding (RHHBY) Reports Strong 1H Results with Growth in Pharmaceuticals Division
Roche Holding (RHHBY) Reports Strong 1H Results with Growth in Pharmaceuticals Division
Roche H1 Profit Drops On Lower Revenues
(RTTNews) - Swiss healthcare major Roche Holding AG (RHHBY, RO.SW) reported Thursday lower profit in its first half with weak revenues.
Roche Backs Full-Year View as First-Half Sales Rise
The drugmaker's sales grew 6% on a constant exchange rate basis and exceeded analysts' expectations, according to a company compiled consensus.
Roche confirms full year targets as first-half sales fall
Swiss drugmaker Roche confirmed its full-year targets on Thursday as first-half sales fell in Swiss franc terms, dragged down by a strong domestic currency.